Document text
Principal Investigator: Patrick Duffy
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $390,420
Funding agency: National Institute of Allergy and Infectious Diseases
In July 2020, we commenced a community COVID-19 seroprevalence study at existing clinical trials sites in Mali. This study is a Public Health Surveillance Activity in collaboration with the Ministry of Health in Mali to describe the sero-epidemiology of COVID-19 in urban and rural populations. Using the demographic and clinical information collected from participants, we will describe the age-stratified seroprevalence and fraction of asymptomatic/pauci-symptomatic cases to help understand the penetration of SARS-CoV-2 into the community. Additional exploratory objectives to understand viral carriage, locally circulating variants, and improve direct virus detection at study sites have been added to help enhance local capacity for Public Health surveillance and possible future clinical trials. Separately, we have leveraged our in-house vaccine platforms to develop COVID-19 vaccine candidates that may be suitable for use in low/middle income countries like Mali.
From our publications this year, we report the following advances in FY2022:
Woodford J, Sagara I, Diawara H, Assadou M, Katile A, Attaher O, Issiaka D, Santara G Soumbounou I, Traore S, Traore M, Dicko O, Niambele S, Mahamar A, Kamate B, Haidara B, Sissoko K, Sankare S, Diarra S, Zeguime A, Doritchamou J, Zaidi I, Dicko A, Duffy PE. Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa. 2022. Frontiers in Immunology. Aug 3.
Malaria has been hypothesized as a factor that may have reduced the severity of the COVID-19 pandemic in sub-Saharan Africa. To evaluate the effect of recent malaria on COVID-19, we assessed a subgroup of individuals participating in a longitudinal cohort COVID-19 serosurvey that were also undergoing intensive malaria monitoring as part of antimalarial vaccine trials during the 2020 transmission season in Mali. These communities experienced a high incidence of primarily asymptomatic or mild COVID-19 during 2020 and 2021. In 1314 individuals, 711 had intercurrent parasitemia; 442 were symptomatic with clinical malaria and 269 had asymptomatic parasitemia. Intercurrent parasitemia was not associated with new COVID-19 seroconversion (29.7% (211/711) vs. 30.0% (181/603), p=0.9038) or with rates of reported symptomatic seroconversion during the malaria transmission season. In the subsequent dry season, prior parasitemia was not associated with new COVID-19 seroconversion (22.0% (133/605) vs. 22.1% (108/488), p>0.9999), with symptomatic seroconversion, or with reversion from seropositive to seronegative (prior parasitemia: 36.2% (64/177) vs. no parasitemia: 30.1% (37/119), p=0.3842). After excluding participants with asymptomatic parasitemia, clinical malaria was also not associated with COVID-19 serostatus or symptomatic seroconversion when compared to participants with no parasitemia during the monitoring period. In communities with intense seasonal malaria and a high incidence of asymptomatic or mild COVID-19, we did not demonstrate a relationship between recent malaria and subsequent response to COVID-19. Lifetime exposure, rather than recent infection, may be responsible for any effect of malaria on COVID-19 severity.
Woodford J, Sagara I, Kwan JL, Zaidi I, Dicko A, Duffy PE. Assessing and minimizing the effect of malaria on SARS-CoV-2 serodiagnostics. 2021. Frontiers in Tropical Diseases. Dec 13.
Malaria may affect the reliability of SARS-CoV-2 seroassay performance and limit understanding of SARS-CoV-2 epidemiology in malaria-endemic regions. We presented our experience conducting SARS-CoV-2 serosurveillance in seasonal malaria-affected communities in Mali and discuss relevant literature regarding the effect of malaria on the performance of SARS-CoV-2 serodiagnostics, including approaches to minimize the effect of malaria-associated assay interference.
Woodford J, Sagara I, Dicko A, Zeguime A, Doucoure M, Kwan J, Zaidi I, Doritchamou JYA, Snow-Smith M, Alani N, Renn JP, Kosik I, Holly J, Yewdell J, Esposito D, Sadtler K, Duffy PE. SARS-CoV-2 seroassay performance and optimization in a population with high background reactivity in Mali. 2021. Journal of Infectious Diseases. Oct 6.
False positivity may hinder the utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests in sub-Saharan Africa. From 312 Malian samples collected before 2020, we measured antibodies to the commonly tested SARS-CoV-2 antigens and 4 other betacoronaviruses by enzyme-linked immunosorbent assay (ELISA). In a subset of samples, we assessed antibodies to a panel of P. falciparum antigens by suspension bead array and functional antiviral activity by SARS-CoV-2 pseudovirus neutralization assay. We then evaluated the performance of an ELISA using SARS-CoV-2 spike protein and receptor-binding domain developed in the United States using Malian positive and negative control samples. To optimize test performance, we compared single- and 2-antigen approaches using existing assay cutoffs and population-specific cutoffs. Background reactivity to SARS-CoV-2 antigens was common in prepandemic Malian samples. The SARS-CoV-2 reactivity varied between communities, increased with age, and correlated negligibly/weakly with other betacoronavirus and P. falciparum antibodies. No pre-pandemic samples demonstrated functional activity. Regardless of the cutoffs applied, test specificity improved using a 2-antigen approach. Test performance was optimal using a 2-antigen assay with population-specific cutoffs (sensitivity, 73.9% 95% confidence interval CI, 51.6-89.8; specificity, 99.4% 95% CI, 97.7-99.9). We have addressed the problem of SARS-CoV-2 seroassay performance in Africa by using a 2-antigen assay with cutoffs defined by performance in the target population.
Manning J, Zaidi I, Lon C, Rosas LA, Park JK, Ponce A, Bohl J, Chea S, Karkanitsa M, Sreng S, Rekol H, Chour CM, Esposito D, Taubenberger JK, Memoli MJ, Sadtler K, Duffy PE, Oliveira F. Pre-pandemic SARS-CoV-2 serological reactivity in rural malaria-experienced Cambodians. 2022. Emerging Infectious Diseases. Feb 1.
Greater Mekong inhabitants are exposed to pathogens, zoonotic and otherwise, that may influence SARS-CoV-2 seroreactivity. A pre-pandemic (2005 to 2011) serosurvey of from 528 malaria-experienced Cambodians demonstrated higher-than-expected (up to 13.8 %) positivity of non-neutralizing IgG to SARS-CoV-2 spike and RBD antigens. These findings have implications for interpreting large-scale serosurveys.
Scaria PV, Rowe CG, Chen BB, Dickey TH, Renn JP, Lambert LE, Barnafo EK, Rausch KM, Tolia NH, Duffy PE. Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. iScience. 2022 Aug 19;25(8):104739. doi: 10.1016/j.isci.2022.104739. Epub 2022 Jul 9. PMID: 35846379; PMCID: PMC9270177.
Receptor binding domain of the SARS-CoV-2 Spike protein was conjugated to a carrier protein. This conjugate has demonstrated significantly higher immunogenicity compared to unconjugated antigen and the immune sera showed high levels of virus neutralizing functional activity against different variants of the SARS-CoV-2 virus. Further studies of this conjugate in non-human primate are ongoing. We also have initiated plan to develop Omicron specific vaccine candidate using this vaccine technology.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><Acute><Address><Affect><Africa><Africa South of the Sahara><Age><Anti-Malarials><Antibodies><Antibody Response><Antigens><Antimalarial Agents><Antimalarial Drugs><Antimalarials><Antisera><Assay><Binding Proteins><Bioassay><Biologic Assays><Biological Assay><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 S protein><COVID-19 affected><COVID-19 antigen><COVID-19 consequence><COVID-19 crisis><COVID-19 disease severity><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 transmission><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cambodian><Carrier Proteins><Clinical><Clinical Trials><CoV-2><CoV2><Collaborations><Communicable Diseases><Communities><Confidence Intervals><ELISA><Emerging Communicable Diseases><Emerging Infectious Diseases><Enzyme-Linked Immunosorbent Assay><Epidemiology><Exposure to><Future><Goals><Health><Holly><Household><IgG><Immune Sera><Immunoglobulin G><Immunology><Incidence><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Journals><LMIC><Ligand Binding Protein><Ligand Binding Protein Gene><Literature><Long-term cohort><Longitudinal cohort><Longterm cohort><Magazine><Malaria><Mali><Measures><Monitor><Outcome><P falciparum><P. falciparum><P.falciparum><Paludism><Parasitemia><Participant><Penetration><Performance><Phase><Plasmodium Infections><Plasmodium falciparum><Population><Population Surveillance><Post-partum Women><Postpartum Women><Pregnant Women><Preparation><Prevalence><Protein Binding><Proteins><Public Health Surveillance><Publications><Reagent><Recombinants><Reporting><Rural><Rural Population><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 antigen><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 transmission><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Scientific Publication><Seasons><Sentinel><Serology><Serology test><Seroprevalences><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Specificity><Sub-Saharan Africa><Subgroup><Subsaharan Africa><Suspension substance><Suspensions><Target Populations><Technology><Testing><Transmission><Transport Protein Gene><Transport Proteins><Transporter Protein><Tropical Disease><United States><Urban Population><Vaccines><Variant><Variation><Viral><Virus><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><ages><anti-malarial agents><anti-malarial drugs><beta CoV><beta coronavirus><betaCoV><betacoronavirus><bound protein><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antigen><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 transmission><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><enzyme linked immunoassay><epidemiologic><epidemiological><expectant mother><expecting mother><experience><frontier><hCoV19><immune serum><immunogen><immunogenicity><improved><low and middle-income countries><malaria transmission><nCoV2><non-human primate><nonhuman primate><pandemic><pandemic disease><parasaetemia><pathogen><performance tests><pregnant mothers><programs><receptor binding><receptor bound><response><seroconversion><serology assay><serology surveillance><serology survey><seropositive><serosurveillance><serosurvey><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 transmission><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><vaccine platform><vaccine study><vaccine trial><viral detection><virus detection><β CoV><β coronavirus><βCoV>